toxylact: a02aa05 Magnesium silicate
The first professional lActological database in the word
Magnesium silicate (ATC A02AA05) is an inorganic magnesium compound, formerly used as an oral antacid and currently used mainly as sterile talc (hydrated magnesium silicate) for chemical pleurodesis.
Definition and classification
Magnesium silicate is the magnesium salt
of silicic acid,
usually expressed as MgSiO3⋅xH2OMgSiO3⋅xH2
O,
and is chemically related to talc (hydrated magnesium
silicate).
In the ATC system it is classified under A02AA05 – magnesium
compounds used as
antacids for acid-related disorders.
Pharmaceutical uses
Historically, orally administered
magnesium silicate was
used as a non‑absorbable antacid to neutralize gastric
hydrochloric acid and
relieve heartburn, dyspepsia, and related upper
gastrointestinal symptoms.
Today, medicinal use as an oral antacid is largely obsolete,
but finely
powdered sterile talc (hydrated magnesium silicate) remains
widely used as a
pleural sclerosing agent for pleurodesis in recurrent
malignant pleural
effusion and spontaneous pneumothorax.
Mechanism of action
As an antacid, magnesium
silicate exerts a local
neutralizing effect in the stomach: it reacts with gastric
hydrochloric acid to
form magnesium chloride and silicon dioxide, reducing
intragastric acidity and
pepsin activity.
As an intrapleural sclerosing agent, sterile talc (hydrated
magnesium silicate)
induces a local inflammatory response of the pleura,
followed by fibroblast
proliferation, collagen deposition, and permanent pleural
symphysis, which
prevents re‑accumulation of air or fluid.
Pharmacokinetics
After oral administration, magnesium
silicate is only
minimally absorbed because it acts locally in the
gastrointestinal lumen and is
rapidly converted to poorly absorbed magnesium salts and
silicon dioxide.
Systemic bioavailability is therefore considered negligible,
and no clinically
relevant human pharmacokinetic parameters have been
established.
General toxicity profile
Experimental data indicate low acute oral
toxicity; reported
animal LD50 values exceed 500 mg/kg, and the compound is not
considered carcinogenic.
Regulatory evaluations classify magnesium silicate and
related silicates as
having low systemic toxicity, although inhalational exposure
to talc powders
can cause pulmonary granulomas and functional impairment,
particularly with
excessive or chronic exposure.
When used for pleurodesis, sterile talc (hydrated magnesium silicate) is an effective pleural irritant, and expected adverse effects include fever, chest pain, and mild restrictive changes in lung function; serious complications are uncommon when large‑particle, asbestos‑free medical talc is used.
Use during lactation – toxicological risk
Oral antacid doses
Clinical experience with antacids during
breastfeeding is
extensive, and magnesium salts (including magnesium
carbonate, magnesium hydroxide,
and magnesium trisilicate) are considered compatible with
breastfeeding at
usual therapeutic doses.
These magnesium salts are poorly absorbed from the maternal
gastrointestinal
tract, and any absorbed magnesium appears naturally in
breast milk; additional
maternal intake is unlikely to meaningfully increase milk
levels or pose a
systemic risk to the breastfed infant.
Magnesium silicate (A02AA05) behaves
similarly as a non‑absorbable
antacid with negligible systemic bioavailability, suggesting
that oral use at
standard doses during lactation carries a low
toxicological risk for
the nursing infant.
On this basis, short‑term, low‑dose oral use of magnesium
silicate for
dyspeptic symptoms in breastfeeding women would be expected
to be compatible
with breastfeeding, provided that maternal renal function is
normal and high
cumulative magnesium exposure from other sources is avoided.
Parenteral / intrapleural use (pleurodesis)
In pleurodesis, sterile talc (hydrated
magnesium silicate)
is administered intrapleurally, with the pharmacological
effect confined to the
pleural cavity and minimal systemic absorption when
appropriate medical
formulations and doses are used.
Available data show mainly local and transient systemic
reactions (fever,
pain); maternal serum levels of magnesium and silicate after
pleurodesis are
not well characterized but are expected to be low relative
to oral exposure
limits.
Given the very limited systemic exposure
and the fact that
magnesium is a normal constituent of breast milk, the
toxicological risk for
the breastfed infant after maternal pleurodesis with medical
talc (magnesium
silicate) is considered low, especially after
the acute post‑procedure
period.
However, because robust lactation‑specific pharmacokinetic
data are lacking for
intrapleural talc, it is prudent to individualize decisions,
monitor the infant
clinically, and consider temporary interruption of
breastfeeding for 12–24
hours in very preterm or medically fragile infants if large
doses or repeated
procedures are required.
Overall lactation safety statement (for your monograph)
- Systemic exposure to magnesium silicate from either oral antacid doses or intrapleural pleurodesis is minimal, and magnesium is a physiological component of human milk.
- Available clinical and regulatory data for related magnesium antacids in breastfeeding women support a low toxicological risk for the breastfed infant when magnesium silicate is used at recommended doses.
- No specific adverse effects in breastfed infants have been reported in association with maternal use of magnesium silicate or medicinal talc; routine infant monitoring beyond standard clinical observation is not usually required.
A possible concise risk classification text you can embed:
“On the basis of negligible systemic absorption, normal presence of magnesium in breast milk, and reassuring data for other magnesium antacids, magnesium silicate is considered compatible with breastfeeding at usual doses; toxicological risk to the breastfed infant is expected to be low. Caution is advised in premature or medically unstable infants and in cases of maternal renal impairment.”



